Last reviewed · How we verify
NCT06967961: DP-PAN-CANCER
Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers
NA trial testing For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes: in Urothelial Carcinoma in 450 participants. Currently enrolling.
23 July 2029
Quick facts
| Lead sponsor | Institut Claudius Regaud |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 450 |
| Start date | 23 July 2025 |
| Primary completion | 23 July 2029 |
| Estimated completion | 23 July 2029 |
| Sites | 1 location across France |
Drugs / interventions tested
- For each enrolled patient, the sample described below will be collected as specific intervention intended for research purposes:
Conditions studied
- Urothelial Carcinoma — all drugs for Urothelial Carcinoma →
- Renal Cancer — all drugs for Renal Cancer →
- Prostate Adenocarcinoma — all drugs for Prostate Adenocarcinoma →
- Adenocarcinoma of Endometrium — all drugs for Adenocarcinoma of Endometrium →
Sponsor
Institut Claudius Regaud — full company profile →
Who can join
18 and older, any sex, with Urothelial Carcinoma or Renal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible patients will be selected and informed of this study during a medical consultation for their cancer by medical oncologists. Then, with the patient's consent and before the start of anti-cancer treatment (whatever the line), a blood sample will be taken to detect DP-circulating cells by 2 different methods of analysis. Each patient will participate in the study for one day. The methods of analysis will be: flow cytometry for all patients and either Parsotix® or CellSearch® depending on the type of cancer. 450 patients will be enrolled in total.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Circulating Tumor Cells in Soft Tissue Sarcoma: Current Evidence and Clinical Implications.
Mendez-Guerra C, Chacon J, Altamirano IE, Calmet Rocca WR, et al · · 2026 · PMID 42192903 · DOI 10.3390/cancers18101542
Verify or expand the search:
- PubMed search for NCT06967961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Urothelial Carcinoma
Currently open trials in the same condition.
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
- NCT07421700 — Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · Phase 1, PHASE2 · recruiting
- NCT07492628 — Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma · Phase 1 · recruiting
- NCT07390617 — A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma · recruiting
Other Institut Claudius Regaud trials
Trials by the same sponsor.
- NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
- NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
- NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
- NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed
- NCT06371339 — Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06967961 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
- Last refreshed: 29 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06967961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing